Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary

What is this summary about? Myelofibrosis is a rare type of bone marrow cancer that causes difficult symptoms such as itching and bone pain. Patients with myelofibrosis may also have an enlarged spleen, develop anemia, and have shorter lives than the general population. This is a summary of an article that used data from the COMFORT studies to examine whether starting treatment with ruxolitinib earlier (within a year of myelofibrosis diagnosis) provided benefits to patients versus delaying ruxolitinib treatment. Patients in the COMFORT-I and COMFORT-II studies who were treated with ruxolitinib lived longer and had improved symptoms compared with patients treated with a placebo (a pill not containing any medicine) or other standard treatments. However, delaying ruxolitinib treatment is common practice in regular healthcare visits for patients who are not part of a clinical study. Therefore, we did an analysis that asked if earlier treatment with ruxolitinib leads to better outcomes than delaying treatment. What were the results? Patients treated with ruxolitinib within a year of diagnosis lived longer,experienced less intense myelofibrosis symptoms such as itching and bone pain, and were less likely to have an enlarged spleen or low blood counts. What do the results mean? Patients with myelofibrosis may benefit from earlier treatment with ruxolitinib (within a year of diagnosis) rather than delaying treatment. These findings are important because they suggest that delaying ruxolitinib treatment in favor of other standard treatments or taking a cautious ’watch and wait’ approach may lead to worse outcomes, including not living as long.